WEST CHESTER

A. Duie Pyle Executives Garner Top Industry Awards for Transformative Leadership in Supply Chain Operations

Retrieved on: 
Monday, March 11, 2024

WEST CHESTER, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- A. Duie Pyle (Pyle), a premier, 100-year-old family-owned and operated provider of asset and non-asset-based supply chain solutions, today announces that three of its esteemed executives have been honored with top industry accolades for their exceptional contributions and exemplary leadership within the supply chain industry.

Key Points: 
  • WEST CHESTER, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- A. Duie Pyle (Pyle), a premier, 100-year-old family-owned and operated provider of asset and non-asset-based supply chain solutions, today announces that three of its esteemed executives have been honored with top industry accolades for their exceptional contributions and exemplary leadership within the supply chain industry.
  • His leadership approach, centered on individual strengths and leveraging technology, has positioned Pyle as an employer of choice in the logistics industry.
  • Her commitment to Pyle and the broader supply chain industry is unparalleled, exemplified by her instrumental roles in various key positions contributing to the company's evolution and success over the years.
  • “Kris and Anna have been pillars of our team, each making invaluable contributions since they joined us,” said Frank Granieri, COO of supply chain solutions at Pyle.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Verrica recognized product revenue of $1.9 million in the fourth quarter of 2023.
  • Verrica reported a net loss of $24.6 million for the fourth quarter of 2023, compared to a $5.9 million net loss for the same period in 2022.
  • Selling, general and administrative expenses were $17.0 million in the fourth quarter of 2023, compared to $3.2 million for the same period in 2022.
  • Research and development expenses were $5.3 million in the fourth quarter of 2023, compared to $3.0 million for the same period in 2022.

fullthrottle.ai Named to Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies

Retrieved on: 
Tuesday, February 27, 2024

147 on its fourth annual Inc. 5000 Regionals: Northeast list, the most prestigious ranking of the fastest-growing Northeast private companies, based in Pennsylvania, New York, Vermont, New Hampshire, Maine, Massachusetts, Connecticut, Rhode Island, and New Jersey.

Key Points: 
  • 147 on its fourth annual Inc. 5000 Regionals: Northeast list, the most prestigious ranking of the fastest-growing Northeast private companies, based in Pennsylvania, New York, Vermont, New Hampshire, Maine, Massachusetts, Connecticut, Rhode Island, and New Jersey.
  • Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Northeast economy’s most dynamic segment–its independent small businesses.
  • “Being named to Inc. Magazine's list of the Northeast's fastest-growing private companies is a testament to the hard work and dedication of our team at fullthrottle.ai,” says CEO David Regn.
  • Complete results of the Inc. 5000 Regionals: Northeast, including company profiles, can be found at inc.com/Northeast .

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
Tuesday, February 27, 2024

WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.

Key Points: 
  • WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.
  • The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
  • A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

Retrieved on: 
Thursday, February 22, 2024

ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.
  • Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13744217.
  • A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com , or by clicking here .
  • A replay of the webcast will be archived on Verrica’s website for 90 days following the event.

fullthrottle.ai Secures Second Patent to Power Unrivaled Attribution Insights for Audio and Video Advertising

Retrieved on: 
Tuesday, February 20, 2024

The patent fortifies fullthrottle.ai ’s already robust product portfolio, powering Smart Impression Predictor, an advanced methodology for probabilistically linking media campaign impressions to user browser sessions and enhancing the precision of media attribution.

Key Points: 
  • The patent fortifies fullthrottle.ai ’s already robust product portfolio, powering Smart Impression Predictor, an advanced methodology for probabilistically linking media campaign impressions to user browser sessions and enhancing the precision of media attribution.
  • This announcement follows the recent launch of SafeMatch™, fullthrottle.ai’s easy-to-use household level attribution solution, the effectiveness of which will now be significantly enhanced by the new patent.
  • The newly patented technology strengthens fullthrottle.ai’s approach to attribution measurement by determining the probability of a user’s browser session being influenced by specific media campaign impressions.
  • The patent will enhance the company's ability to offer precise and effective attribution methods, crucial for brands who want to understand and maximize the impact of their advertising efforts.

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

Retrieved on: 
Monday, February 5, 2024

WEST CHESTER, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc., a Canada corporation (“Dormer Labs”) requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs’ violations of the federal Lanham Act and Pennsylvania law. The lawsuit arises out of Dormer Labs’ false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.

Key Points: 
  • The lawsuit arises out of Dormer Labs’ false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.
  • YCANTH was the first FDA-approved treatment for molluscum contagiosum.
  • YCANTH is also the only FDA-approved cantharidin-containing drug, meaning that it is the only cantharidin-containing drug that FDA has determined to be safe and effective.
  • This lawsuit is part of Verrica’s commitment to patient safety by stopping the false and misleading advertising and sale of unapproved cantharidin-containing drugs within the United States.

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

Retrieved on: 
Monday, January 29, 2024

Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH™ will become fully published April 1, 2024.

Key Points: 
  • Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH™ will become fully published April 1, 2024.
  • J-codes help determine how managed care organizations reimburse medical providers for products and services.
  • Inaccurately reporting medical services can cause insurance complications and make it harder to get rebates.
  • Using a standardized code reduces the risk of billing errors and allows companies to receive pass-through payments through government-sponsored healthcare plans.1

DealerOn and Stream Companies Announce Strategic Alliance, Launch Unrivaled Suite of Integrated Products and Services Anchored by a Premier Connected Client Experience

Retrieved on: 
Friday, January 26, 2024

This collaboration marks a significant milestone in delivering a unified solution to meet the diverse needs of automotive dealerships.

Key Points: 
  • This collaboration marks a significant milestone in delivering a unified solution to meet the diverse needs of automotive dealerships.
  • “The market is overwhelmed with countless vendors offering siloed marketing solutions with poor customer experience, a lack of integration, and misinformation surrounding digital advertising and AdTech.
  • The noise became too loud to ignore and a problem we needed to solve urgently,” said David Regn, co-founder, and CEO of Stream Companies.
  • Provide DealerOn and Stream clients with access to advanced website and conversion technology, powered by patented technology.

A. Duie Pyle Expands Industry-Leading Northeast Footprint with New Facility Opening in Maine

Retrieved on: 
Tuesday, January 16, 2024

The opening of this facility marks the company's first expansion in 2024, the year of its centennial.

Key Points: 
  • The opening of this facility marks the company's first expansion in 2024, the year of its centennial.
  • Upon opening, the facility added 12 new jobs to the local economy, with another nine coming by the end of the year.
  • Pyle previously had one LTL service center located in Portland, Maine, so this expansion allows for more comprehensive, full-service coverage across the state.
  • "We’re kicking 2024 off with a bang, as this new facility enables us to solidify our industry-leading presence across the Northeast,” said John Luciani, COO of LTL Solutions at A. Duie Pyle.